Loading...
XKRX200230
Market cap458mUSD
Dec 09, Last price  
5,980.00KRW
Name

Telcon RF Pharmaceutical Inc

Chart & Performance

D1W1MN
XKRX:200230 chart
P/E
48.11
P/S
18.43
EPS
124.30
Div Yield, %
0.00%
Shrs. gr., 5y
14.18%
Rev. gr., 5y
-8.85%
Revenues
36.31b
+30.46%
35,223,848,24046,638,653,45058,756,395,20028,542,710,49529,840,249,47641,149,342,28657,708,456,06852,478,096,80333,141,153,91037,841,150,31527,829,999,16936,307,203,770
Net income
13.91b
P
4,478,716,7907,889,196,8106,741,459,320348,205,166-3,438,171,142-16,440,417,431-13,754,594,876-52,648,899,647-40,892,851,943-23,098,051,471-42,084,350,43813,906,405,519
CFO
-1.13b
L-45.78%
1,921,810,48012,616,833,7901,473,391,6802,267,158,491-3,969,489,818-9,868,413,228-9,249,386,6985,012,725,8542,802,856,787-358,558,813-2,092,882,466-1,134,685,920
Earnings
Mar 17, 2025

Profile

TELCON RF PHARMACEUTICAL. Inc. develops, produces, and sells RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is based in Yongin-si, South Korea.
URL
https://www.telcon.co.kr/
IPO date
Nov 24, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
36,307,204
30.46%
27,829,999
-26.46%
37,841,150
14.18%
Cost of revenue
28,800,426
27,622,109
36,639,270
Unusual Expense (Income)
NOPBT
7,506,778
207,890
1,201,880
NOPBT Margin
20.68%
0.75%
3.18%
Operating Taxes
(1,979,114)
(32,809)
(108,797)
Tax Rate
NOPAT
9,485,892
240,699
1,310,677
Net income
13,906,406
-133.04%
(42,084,350)
82.20%
(23,098,051)
-43.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
27,020,267
29,547,364
54,635,280
Long-term debt
1,383,196
1,455,701
2,601,939
Deferred revenue
Other long-term liabilities
143,412
62,771
7,907
Net debt
(56,915,103)
(42,938,807)
(57,109,753)
Cash flow
Cash from operating activities
(1,134,686)
(2,092,882)
(358,559)
CAPEX
(1,897,846)
(833,955)
(5,813,478)
Cash from investing activities
(10,524,640)
(7,885,465)
879,019
Cash from financing activities
10,445,303
(3,440,268)
(1,891,222)
FCF
3,101,277
1,594,585
2,070,789
Balance
Cash
10,519,043
9,733,525
23,195,461
Long term investments
74,799,523
64,208,346
91,151,512
Excess cash
83,503,206
72,550,372
112,454,916
Stockholders' equity
(139,155,703)
(149,331,594)
(105,841,036)
Invested Capital
271,666,936
263,804,893
268,392,839
ROIC
3.54%
0.09%
0.49%
ROCE
5.67%
0.18%
0.74%
EV
Common stock shares outstanding
149,546
106,081
87,849
Price
873.00
-13.99%
1,015.00
-65.30%
2,925.00
-51.73%
Market cap
130,553,376
21.25%
107,672,585
-58.10%
256,957,547
-50.46%
EV
74,123,736
64,746,035
199,875,379
EBITDA
11,751,015
4,489,354
5,401,861
EV/EBITDA
6.31
14.42
37.00
Interest
603,578
1,062,740
7,701,980
Interest/NOPBT
8.04%
511.20%
640.83%